Analytical Data
-
Gene name
COL17
- Application
-
Alternative Names
COL17A1; BP180; BPAG2; LAD-1; LABD97; Collagen Alpha-1(XVII)chain; 180 kDa bullous pemphigoid antigen 2; Bullous pemphigoid antigen 2; Linear IgA disease antigen 1
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9UMD9
-
Expression Region
Pro184~Pro375
-
Molecular Weight
23kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Collagen XVII (COL17), also known as BP180, is a transmembrane protein that plays a crucial role in skin adhesion by anchoring the basement membrane to the underlying dermis. It is predominantly expressed in epithelial tissues, especially in the skin, where it is essential for maintaining the structural integrity of the epidermal-dermal junction. The significance of COL17 has gained attention due to its involvement in various autoimmune diseases, particularly bullous pemphigoid, where autoantibodies against COL17 lead to skin blistering. Additionally, COL17 is also implicated in cancer progression and metastasis, making it a potential therapeutic target. Recent advances in recombinant protein technology have enabled the production of COL17 for research and clinical applications, allowing for a better understanding of its function, interactions, and pathological implications. The study of recombinant COL17 facilitates the exploration of its diagnostic and therapeutic potential in autoimmune disorders and cancer, offering insights into possible interventions that could mitigate disease progression or offer novel treatments. As such, the investigation of COL17 recombinant protein is critical for elucidating its role in both skin pathology and system-wide health, presenting opportunities for targeted therapies and improved patient outcomes.
